Therapeutic | Erenumab |
Target | CALCRL |
Heavy Chain | QVQLVESGGGVVQPGRSLRLSCAASGFTFSSFGMHWVRQAPGKGLEWVAVISFDGSIKYSVDSVKGRFTISRDNSKNTLFLQMNSLRAEDTAVYYCARDRLNYYDSSGYYHYKYYGMAVWGQGTTVTVSS |
Light Chain | QSVLTQPPSVSAAPGQKVTISCSGSSSNIGNNYVSWYQQLPGTAPKLLIYDNNKRPSGIPDRFSGSKSGTSTTLGITGLQTGDEADYYCGTWDSRLSAVVFGGGTKLTVL |
100% seqID Fv Structure | 6umh [Fvs: HL], 6umi [Fvs: HL], 6umj [Fvs: HL] |
99% seqID Fv Structure | None |
95-98% seqID Fv Structure | None |
100% seqID Structure | 6umh [Fvs: HL] |
100% seqID Structure | 6umi [Fvs: HL] |
100% seqID Structure | 6umj [Fvs: HL] |
Follow these links to our prediction tools:
Format | Whole mAb |
Isotype | G2 |
Highest Clinical Trial (June '19) | Approved |
Estimated Status (June '19) | NFD |
Recorded Developmental Technology | Abgenix XenoMouse |
INN Year Proposed | 2016 |
INN Year Recommended | 2017 |
Companies Involved | Amgen, Novartis |
Conditions Approved | Migraine |
Conditions Active | na |
Conditions Discontinued | Hot flashes |
Notes |